Fredericamycin A, a new antitumor antibiotic. II. Biological properties.
Fredericamycin A is a novel antibiotic produced by a soil isolate of Streptomyces griseus (FCRC-48). In vitro, fredericamycin A exhibits antibacterial, antifungal, and cytotoxic activities. In vivo, fredericamycin A exhibits very good antitumor activity against P388 mouse leukemia as well as the CD8F mammary tumor and marginal activity against B16 melanoma. Fredericamycin A failed to demonstrate any interaction with DNA and inhibited protein and RNA synthesis preferentially to DNA synthesis in Bacillus subtilis and P388 cells.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D004247:DNA / Q000378:metabolism; D007546:Isoquinolines / Q000494:pharmacology; D051379:Mice; D008826:Microbial Sensitivity Tests; D009153:Mutagens; D009374:Neoplasms, Experimental / Q000188:drug therapy; D013141:Spiro Compounds / Q000494:pharmacology
D000903:Antibiotics, Antineoplastic; D007546:Isoquinolines; D009153:Mutagens; D013141:Spiro Compounds; D004247:DNA; C016660:fredericamycin A